Second-Generation Antipsychotics for Depression in Serious Illness: A First-Line Augmentation Strategy

Area of Science:

• Palliative Care
• Psychiatry
• Pharmacology

Background:

• Depression is prevalent and disabling in serious illness, often necessitating swift symptom improvement.
• Traditional antidepressants have a slow onset of action, typically requiring weeks for therapeutic effects.
• Second-generation antipsychotics (SGAs) demonstrate faster onset and augmentation efficacy in general psychiatric conditions.

Purpose of the Study:

• To review evidence for using SGAs in treating depression within serious illness contexts.
• To evaluate SGAs as both monotherapy and augmentation strategies for depression.
• To assess the potential for rapid symptom improvement in palliative care patients.

Main Methods:

• Literature review of psychiatric and serious illness-specific evidence for SGAs.
• Analysis of randomized controlled trials (RCTs) and observational data.
• Examination of safety profiles in cancer patient populations.

Main Results:

• SGA augmentation in psychiatric populations improved response/remission rates (ORs 1.34-2.93, NNT 7-13) with 1-2 week onset.
• SGA monotherapy is less tolerated and not guideline-recommended.
• While no serious illness-specific psychiatric RCTs exist, cancer trials support SGA safety for various symptoms.

Conclusions:

• SGAs possess the strongest evidence among augmentation options for depression in serious illness.
• Early, low-dose SGA augmentation may provide significant benefits when rapid improvement is crucial.
• Consider SGAs early for depression, especially when they can concurrently manage physical symptoms relevant to palliative care.